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A B S T R A C T
Cyclooxygenase-2 (COX-2), with its main antiﬁbrotic metabolite PGE2, is regarded as an antiﬁbrotic gene.
Repressed COX-2 expression and deﬁcient PGE2 have been shown to contribute to the activation of lung ﬁ-
broblasts and excessive deposition of collagen in pulmonary ﬁbrosis. We have previously demonstrated that
COX-2 expression in lung ﬁbroblasts from patients with idiopathic pulmonary ﬁbrosis (IPF) is epigenetically
silenced and can be restored by epigenetic inhibitors. This study aimed to investigate whether COX-2 down-
regulation induced by the proﬁbrotic cytokine transforming growth factor-β1 (TGF-β1) in normal lung ﬁbro-
blasts could be prevented by epigenetic inhibitors. We found that COX-2 protein expression and PGE2 production
were markedly reduced by TGF-β1 and this was prevented by the pan-histone deacetylase inhibitor sub-
eranilohydroxamic acid (SAHA) and to a lesser extent by the DNA demethylating agent Decitabine (DAC), but
not by the G9a histone methyltransferase (HMT) inhibitor BIX01294 or the EZH2 HMT inhibitor 3-deazane-
planocin A (DZNep). However, chromatin immunoprecipitation assay revealed that the eﬀect of SAHA was
unlikely mediated by histone modiﬁcations. Instead 3′-untranslated region (3′-UTR) luciferase reporter assay
indicated the involvement of post-transcriptional mechanisms. This was supported by the downregulation by
SAHA of the 3′-UTR mRNA binding protein TIA-1 (T-cell intracellular antigen-1), a negative regulator of COX-2
translation. Furthermore, TIA-1 knockdown by siRNA mimicked the eﬀect of SAHA on COX-2 expression. These
ﬁndings suggest SAHA can prevent TGF-β1-induced COX-2 repression in lung ﬁbroblasts post-transcriptionally
through a novel TIA-1-dependent mechanism and provide new insights into the mechanisms underlying its
potential antiﬁbrotic activity.
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T
HDAC histone deacetylase
H3K9me3 histone H3 lysine 9 trimethylation
ARE AUUUA-rich element
HuR human antigen R
ELAV1 ELAV-like RNA binding protein 1
TTP Tristetraprolin
CUGBP2 CUG triplet repeat, RNA binding protein 2
F-NL ﬁbroblast from non-ﬁbrotic lung
FCS fetal calf serum
1. Introduction
Activated lung ﬁbroblasts (myoﬁbroblasts) are characterized by
their ability to express α-smooth muscle actin (α-SMA) and secrete
extracellular matrix (ECM) proteins, particularly collagen 1 (COL1).
They are regarded as key eﬀector cells in pulmonary ﬁbrosis, particu-
larly in idiopathic pulmonary ﬁbrosis (IPF), a fatal lung disease with
unknown aetiology and a lack of speciﬁc eﬀective therapies.
Experimental evidence points to the proﬁbrotic cytokine transforming
growth factor-β (TGF-β1) as an important driving factor of ﬁbrosis in-
itiation and progression. TGF-β1 has been shown to induce ﬁbroblast
activation, excessive production of ECM and inhibition of ECM de-
gradation [1]. Blocking TGF-β1 eﬀectively reduced lung ﬁbrosis in
animal models, and inhibition of TGF-β1 signalling slowed the pro-
gression of IPF in patients [2]. But pan-TGF-β blocking shows lack of
eﬃcacy and causes pleiotropic eﬀects.
Prostaglandin E2 (PGE2) is a potent antiﬁbrotic mediator. It inhibits
ﬁbroblast-to-myoﬁbroblast diﬀerentiation and many pro-ﬁbrotic fea-
tures of lung myoﬁbroblasts, including proliferation, migration, and
collagen production. However, both lung ﬁbroblasts isolated from IPF
patients and TGF-β1-activated lung ﬁbroblasts have been shown to be
associated with reduced PGE2 production as a result of down-regulation
of cyclooxygenase-2 (COX-2), a rate-limiting enzyme responsible for
PGE2 production [3–5]. Reduced COX-2 expression has also been ob-
served in bronchial epithelial cells of IPF patients, suggesting that COX-
2 downregulation is not limited to lung ﬁbroblasts [6]. Furthermore,
COX-2-deﬁcient mice, having limited PGE2 synthesis, are more sus-
ceptible to bleomycin-induced pulmonary ﬁbrosis [7]; in contrast, COX-
2 overexpression in the lung leads to increased PGE2 synthesis and re-
duced ﬁbroblast proliferation [8]. These observations suggest that the
antiﬁbrotic COX-2/PGE2 mechanism is lost in ﬁbrotic lung due to COX-
2 repression.
Epigenetic regulation of gene expression is a key mechanism in the
activation or silencing of genes. DNA methylation at CpG islands in
gene promoter regions catalysed by DNA methyltransferases (DNMTs)
is usually associated with gene silencing. Acetylation and deacetylation
of histone lysine residues by histone acetyltransferases (HATs) and
histone deacetylases (HDACs) are associated with transcriptional acti-
vation and repression, respectively. Methylation of lysine residues at
histone H3 and H4 tails can be associated with either transcriptional
activation or repression depending on the speciﬁc site and the number
of methyl groups added. Trimethylation of H3 lysine 9 and 27
(H3K9me3, H3K27me3) by histone methyltransferase (HMT) G9a and
EZH2 (enhancer of zeste homolog 2), respectively, are enriched in
transcriptionally repressed promoter regions, whereas H3K4me3 by the
Trithorax complex is enriched in active promoter regions [9]. We have
previously reported that in lung ﬁbroblasts from IPF patients, the COX-
2 promoter region is associated with repressive histone modiﬁcations,
i.e. H3 and H4 deacetylation and H3K9 and H3K27 methylation. Fur-
thermore, epigenetic inhibitors LBH589 (panobinostat, a pan-HDAC
inhibitor), BIX02189 (a G9a inhibitor) or 3-deazaneplanocin A (DZNep,
an EZH2 inhibitor), can restore COX-2 expression and PGE2 production
by reversing the repressive histone modiﬁcations [3,5].
Post-transcriptional mechanisms also play a critical role in reg-
ulating COX-2 expression, conferred by the conserved AUUUA-rich
elements (AREs) located in the 3′-untranslated region (3′-UTR) of COX-
2 transcripts. AREs function to target mRNA for rapid decay or stabi-
lization and to promote or inhibit translation, depending on the speciﬁc
ARE binding proteins or microRNAs [10]. Diﬀerent ARE binding pro-
teins have been found to regulate COX-2 post-transcriptionally, espe-
cially in colon cancer [11]. Among them, HuR (human antigen R), also
known as ELAV-like RNA binding protein 1 (ELAV1), displays high af-
ﬁnity for AREs and stabilizes ARE-containing mRNAs and promotes
their translation upon binding [12]. HuR is overexpressed in colon
adenomas and adenocarcinomas and its ability to target 3′-UTR-medi-
ated COX-2 upregulation has been demonstrated in colon cancer cells
[13]. Tristetraprolin (TTP) has been reported to promote rapid mRNA
decay [14] and is involved in COX-2 downregulation in colon cancer
cells, driving COX-2 mRNA for rapid degradation [13,15]. CUG triplet
repeat, RNA binding protein 2 (CUGBP2), similarly to HuR, increases
COX-2mRNA stability, but also inhibits COX-2 protein translation [16].
T-cell intracellular antigen-1 (TIA-1) has been shown to bind to ARE in
the 3′-UTR of COX-2 transcripts and functions as a translational silencer
of COX-2 [15,17].
Suberanilohydroxamic acid (SAHA) (trade name Vorinostat), is a
non-selective HDAC class 1 and 2 inhibitor and has been approved for
the treatment of peripheral and cutaneous T-cell lymphoma by the Food
and Drug Administration (FDA) of the US. It is under evaluation for the
treatment of non-small cell lung cancer in combination with DNA de-
methylating agents and chemotherapy [18]. SAHA has been shown to
abrogate TGF-β1-induced lung ﬁbroblast activation and collagen ex-
pression [36] and signiﬁcantly reduce collagen deposition in a murine
model of bleomycin-induced pulmonary ﬁbrosis [19,20], suggesting
promising antiﬁbrotic potential, however the underlying molecular
mechanisms are not clear yet. Although SAHA, as a HDAC inhibitor, can
regulate gene expression through transcriptional activation, there is
evidence that it can also regulate gene expression post-transcriptionally
by increasing mRNA stabilization [21] and suppressing protein trans-
lation [22]. However, how SAHA may modulate COX-2 expression and
the release of the antiﬁbrotic mediator PGE2 in TGF-β1-induced lung
ﬁbroblast activation remains to be clariﬁed.
Since epigenetic inhibitors have been shown to restore COX-2 ex-
pression and PGE2 production in lung ﬁbroblasts from IPF patients by
reversing the repressive histone modiﬁcations [3,5], the aim of this
study was to evaluate the eﬀect of these drugs on COX-2 down-
regulation associated with TGF-β1-induced activation of normal human
lung ﬁbroblasts. The results presented here demonstrate that the pan-
HDAC inhibitor SAHA is the most promising among the inhibitors
tested in upregulating COX-2 protein expression and PGE2 production
and that its eﬀect is mainly mediated via a novel post-transcriptional
mechanism by supressing the expression of the translational repressor
ARE binding protein TIA-1. This mechanism may contribute to the
antiﬁbrotic eﬀect of SAHA.
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2. Materials and methods
2.1. Fibroblast cell culture
Fibroblast from non-ﬁbrotic lung (F-NL) obtained from the
University of Pittsburgh Medical Center (Pittsburgh, PA, USA) were
isolated from normal lung tissues from organ donors under a protocol
approved by the University of Pittsburgh Institutional Review Board
and cultured as described previously [23]. The four donors included
two males and two with undisclosed gender; the age of one donor was
undisclosed and the average age of the other three donors was
46.7 years (range, 27–63). One donor was a nonsmoker and the
smoking history of the other three was undisclosed. The cells were
grown to passage six in DMEM with 10% foetal calf serum (FCS)
(complete DMEM) as described before [5]. They were seeded up to 24 h
before starting the treatments to ensure an exponential growth phase.
They were then pre-treated with the G9a inhibitor BIX01294 (BIX,
100 nM), the EZH2 inhibitor 3-Deazaneplanocin A (DZNep, 10 nM), the
HDAC inhibitor suberanilohydroxamic acid (SAHA, 5 μM, Cayman
Chemical, Ann Arbor MI, USA), the hypomethylating agent Decitabine
(DAC, 1 μM, Biovision, Milpitas, CA, USA), or vehicle, for 1 h prior to
incubation with recombinant human TGF-β1 (2 ng/ml, Peprotech,
London, UK) for 96 h (48 h in complete DMEM followed by 48 h in
serum-free DMEM), in combination with recombinant human IL-1β
(1 ng/ml, Peprotech) for up to the last 24 h. At the indicated time
points, cells were collected for subsequent analyses.
2.2. Quantitative real-time RT-PCR (qRT-PCR)
qRT-PCR was applied to analyze mRNA expression of genes. After
4 h of IL-1β stimulation, total RNA was extracted from F-NL cells using
the NucleoSpin® RNA (Macherey Nagel, Düren, Germany) following the
manufacturer's instruction. 500 ng of total mRNA was reverse tran-
scribed to cDNA with the High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA). cDNA was then diluted
10 times and 5 μl were ampliﬁed using 1 μM primers and the KAPA
SYBR® FAST qPCR Kit (Roche Diagnostics, West Sussex, UK). The re-
lative quantitation was calculated with the 2−ΔΔCT method using
GAPDH as reference gene. The primer sequences used are: GAPDH
forward 5′-ACAGTTGCCATGTAGACC-3′ and reverse 5′-TTTTTGGTTG
AGCACAGG-3′; COX-2 forward 5′-AAGCAGGCTAATACTGATAGG-3′
and reverse 5′-TGTTGAAAAGTAGTTCTGGG-3′; ELAV1 forward
5′-GATCAGACTACAGGTTTGTC-3′ and reverse 5′-TTGAAACTGGTAAT
TGCCTC-3′; TIA-1 forward 5′-GACTTTTTCACCATTTGGAC-3′ and re-
verse 5′-ACTTTCATGGGAATTGAACC-3′; ZEP36 forward 5′-CAAGTAA
TCCCCT TTTCCAG-3′ and reverse 5′-CACCATCATGAATACTGAGC-3′.
2.3. Western blotting
After 24 h IL-1β stimulation, F-NL cells were lysed with RIPA buﬀer
and frozen at −80 °C. Proteins were puriﬁed with high speed cen-
trifugation and their concentration was determined by bicinchoninic
acid (BCA) assay (ThermoFisher, Waltham, MA, USA). Proteins were
diluted with 4× Laemmli buﬀer and boiled for 10min. 10–20 μg of
total protein were separated with SDS-PAGE and transferred into PVDF
membrane. After 1 h blocking with 5% Blotto non-fat dry milk (Santa
Cruz, Active Santa Cruz, CA, USA) in TBS 0.05% tween 20, the mem-
branes were incubated with speciﬁc antibodies recognizing human
forms of COX-2 (160112, Cayman Chemical), GAPDH (sc-47724, Santa
Cruz), α-Tubulin (sc-8035, Santa Cruz), α-SMA (ab5694, Abcam,
Cambridge, UK), COL1 (ab34710, Abcam) and TIA-1 (sc-1751, Santa
Cruz). The optical densitometry (OD) of the protein bands was analyzed
using Image Lab™ Software (Bio-Rad, Hercules, CA, USA). Data were
normalized with the loading control GAPDH or α-Tubulin and fold
changes from control condition were calculated.
2.4. Chromatin immunoprecipitation (ChIP)
F-NL cells were crosslinked using 1% formaldehyde after 72 h of
treatment with SAHA in the presence or absence of TGF-β1 stimulation.
ChIP assays were performed using the ChIP-IT Express Kit (53008,
Active Motif, Carlsbad, CA, USA) as described previously [5]. Anti-
bodies against acetylated histone H3 (06-599, Merck Millipore, Bill-
erica, MA, USA), H3K27me3 (07-499, Merck Millipore), or normal
rabbit IgG (12-370, Merck Millipore) were used for immunoprecipita-
tion. 5 μl of puriﬁed immunoprecipitated-DNA was ampliﬁed using
real-time PCR ampliﬁcation with primers (0.5 μM) designed speciﬁcally
for the COX-2 promoter region (set A and B, Fig. 2A) and the KAPA
SYBR® FAST qPCR Kit (KK4602, Roche Diagnostics). The primer se-
quences were the following: Set A forward 5′-ACAGCCTATTAAGCGT
CGTCA-3′ and reverse 5′-CCGTGTCTGGTCTGTACGTC-3′, Set B forward
5′-AGCTTCCTGGGTTTCCGATT-3′ and reverse 5′-AGCCCATGTGACGA
AATGACT-3′. ChIP data were analyzed using the Percent Input (%
Input) method. Brieﬂy, input Ct values corresponding to 1% of initial
chromatin were adjusted to 100% and used to normalize Ct values of
immunoprecipitated-DNA samples. ChIP PCR was performed in dupli-
cate and the results were presented as mean ± SEM of three in-
dependent biological replicates (cell lines).
2.5. Bisulﬁte sequencing
Genomic DNA from F-NL cells was extracted with a standard pro-
cedure using phenol-chloroform. Bisulﬁte conversion of DNA (1 μg) was
conducted with the EZ DNA Methylation™ Kit (D5001, Zymo Research,
Irvine, CA, USA) following the manufacturer's instructions. COX-2
promoter region was ampliﬁed using 1 μM primers (primer sequences:
forward 5′-GGTAGGAAATTTTATATTGGTGATT-3′ and reverse 5′-CTC-
ACCTATATAACTAAACRCCA-3′), 2.5 mM MgCl2, 1 μl HotStarTaq Plus
DNA Polymerase (203601, Qiagen, Venlo, NL). Agarose gel electro-
phoresis was used to separate PCR products. DNA bands corresponding
to COX-2 promoter were dissected under UV-light and the DNA was
extracted using the QIAquick Gel Extraction Kit (28704, Qiagen) fol-
lowing the manufacturer's instructions. DNA was then cloned using the
pGEM®-T Easy Vector System II (A1380, Promega, Madison, WI, USA).
Plasmids from 8 clones of each line were extracted using the QIAprep
Spin Miniprep Kit (27104, Qiagen) following the manufacturer's in-
structions and were sequenced with a 3130xl ABI PRISM Genetic
Analyzer (Life Technologies, Carlsbad, CA, USA).
2.6. COX-2 3′-UTR luciferase assay
COX-2 3′-UTR (2.75 Kb) was ampliﬁed using COX-2 BAC DNA
(Clone RP5 973-M2, Human BAC Resources) as a template. The forward
and reverse PCR primers were designed to harbour SacI and XhoI re-
striction sites, respectively. The primer sequences were the following:
forward 5′-CTCTGAGCTCCAATGCAAGTTCTTCCCGCT-3′ and reverse
5′-CTCTCTCGAGTTTCCAACACAGTGTCGCAG-3′. 1 μg of puriﬁed PCR
products was then digested using SacI (R6061, Promega) and XhoI
(R6161, Promega) restriction enzymes following the manufacturer's
instructions. Digestion was then checked by agarose electrophoresis.
Digested DNA was then ligated into the pmirGLO Dual-Luciferase
miRNA Target Expression Vector (E1330, Promega) and cloned in
JM109 competent cells (L200A, Promega). Plasmid harbouring COX-2
3′-UTR cloned downstream the ﬁreﬂy luciferase gene sequence was
then ampliﬁed and puriﬁed.
F-NL cells were seeded into a 96 multiwell plate and pretreated with
5 μM SAHA or vehicle for 1 h prior to treatment with 2 ng/ml TGF-β1
for 48 h in complete DMEM. Cells were then transfected using FuGENE®
HD Transfection Reagent (E2311, Promega) with the empty vector or
the vector harbouring COX-2 3′-UTR. Brieﬂy 250 ng of plasmid was
incubated with 0.75 μl of transfection reagent for 15min at room
temperature in 10 μl ﬁnal volume of serum-free DMEM. The
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transfection mix was then added to the well containing 90 μl of fresh
serum-free and antibiotic-free DMEM and the cells were incubated at
37 °C, 5% CO2 in a humidiﬁed incubator for 3 h. The cells were then
treated with SAHA and TGF-β1 for additional 48 h in serum-free DMEM
and with 1 ng/ml IL-1β for the last 24 h. Fireﬂy and Renilla luciferase
activities were then measured using the Dual-Glo® Luciferase Assay
System (E2920, Promega) following the manufacturer's instruction. The
relative luciferase activity was calculated as the ratio between Fireﬂy
luciferase activity and Renilla luciferase activity. Reduced relative lu-
ciferase activity indicates decreased transcript stability and/or trans-
lation. Data were presented as mean ± SEM of three biological re-
plicates.
2.7. mRNA stability assay
F-NL cells were pre-treated with 5 μM SAHA for 1 h prior to treat-
ment with 2 ng/ml TGF-β1 for 72 h (48 h in complete DMEM followed
by 24 h in serum-free DMEM). COX-2mRNA expression was induced by
1 ng/ml IL-1β for 2 h before the addition of 5 μM Actinomycin D (ActD)
to stop mRNA synthesis. Total mRNA was isolated at 0, 2, 8, and 24 h
post ActD treatment. COX-2 mRNA expression was analyzed by qRT-
PCR as described above. % change over control at 0 h ActD was then
calculated.
2.8. siRNA transfection
F-NL cells were seeded in a 12 well plate (35,000 cells/well) in
250 μl of serum-free and antibiotic-free DMEM and transfected using
HiPerFect Transfection Reagent (301704, Qiagen) and TIA-1 siRNA
(SMARTpool: siGENOME TIA-1 siRNA, M-013042-02-0005, Darmacon
Lafayette, CO, USA) or negative control siRNA negative control
(1022076, Qiagen). Brieﬂy, 60 nM TIA-1 siRNA or control siRNA were
incubated with 6 μl of transfection reagent for 10min at room
temperature in 250 μl ﬁnal volume of media. The transfection mix was
then added to the well and the cells were incubated at 37 °C, 5% CO2 in
a humidiﬁed incubator for 3 h. After the addition of 500 μl complete
DMEM to each well, the cells were then treated with TGF-β1 for 48 h.
The transfection and TGF-β1 treatment were then repeated in serum-
free and antibiotic-free DMEM and cells were treated with 1 ng/ml IL-
1β for the last 24 h. Cells were then harvested for TIA-1 and COX-2
protein analysis by Western blotting.
2.9. PGE2 assay
PGE2 concentration in the culture medium was quantiﬁed using the
Prostaglandin E2 ELISA Kit (514010, Cayman Chemical) following the
manufacturer's instruction. The values obtained were adjusted with the
total amount of protein per well.
2.10. Statistics
Data are presented as mean ± SEM from experiments using at least
three diﬀerent cell lines. Statistical analysis was performed using
GraphPad Prism 6®. Student's t-test was performed to determine the
signiﬁcance of diﬀerences between two means. One way ANOVA was
used to compare multiple conditions. A p value < 0.05 was accepted as
statistically signiﬁcant.
3. Results
3.1. SAHA prevents TGF-β1-induced downregulation of COX-2 in F-NL
To ﬁnd out whether COX-2 could be downregulated in TGF-β1-in-
duced lung ﬁbroblast activation, F-NL cells were stimulated with TGF-
β1 for 72 h. As reported before, TGF-β1-treated cells displayed a myo-
ﬁbroblast phenotype characterized by the upregulation of the ﬁbrotic
Fig. 1. Eﬀect of epigenetic inhibitors on COX-2 gene expression and PGE2 production. F-NL from 3 donors were pre-treated with the epigenetic inhibitors (100 nM BIX01294, 10 nM
DZNep, 5 μM SAHA and 1 μM DAC) for 1 h prior to incubation with TGF-β1 (2 ng/ml) for 96 h, before further incubation with IL-1β (1 ng/ml) to induce COX-2 for 4 (for mRNA
expression) and 24 (for protein expression) h. A, A representative Western blotting showing the eﬀects of the epigenetic inhibitors on the protein expression of COX-2. B, Optical
densitometry analysis of Western blotting bands for A. Data were normalized with the loading control GAPDH. Fold changes from control cells (CTL) were calculated. C, COX-2 mRNA
analysis by qRT-PCR using GAPDH as reference gene (2−ΔΔCT method). Fold changes from control cells were calculated. D, A representative Western blotting showing the eﬀects of SAHA
on the protein expression of COX-2. E, Optical densitometry analysis of Western blotting bands for D. Data were normalized with the loading control GAPDH. Fold changes from control
cells were calculated. F, PGE2 concentration in the media was analyzed by ELISA. All data are reported as mean ± SEM of three biological replicates (cell lines). *p < 0.05; **p < 0.01;
***p < 0.001.
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markers collagen 1 (COL1) and α-smooth muscle actin (α-SMA) com-
pared with unstimulated control cells (Supplementary Fig. 1). COX-2
protein was not constitutively expressed in F-NL, but was induced by
treatment with IL-1β for 24 h. However, in TGF-β1-treated cells, IL-1β-
induced COX-2 expression was signiﬁcantly reduced compared with
cells treated with IL-1β alone (Fig. 1A and B). Among the tested epi-
genetic inhibitors, the pan-HDAC inhibitor SAHA and the DNA hypo-
methylating agent DAC prevented TGF-β1-induced COX-2 down-
regulation, but the G9a inhibitor BIX01294 (BIX) and the EZH2
inhibitor DZNep displayed no eﬀect on COX-2 expression (Fig. 1A and
B). COX-2mRNA was undetectable in control cells, IL-1β also induced a
signiﬁcant increase of COX-2 mRNA in F-NL. A modest, but insignif-
icant reduction of COX-2 mRNA was observed following TGF-β1
treatment, but none of the epigenetic inhibitors caused any signiﬁcant
change of COX-2 mRNA compared with TGF-β1 treatment alone
(Fig. 1C). SAHA alone had no eﬀect on COX-2 protein expression, but
was also able to upregulate IL-1β-induced COX-2 protein expression in
F-NL with or without TGF-β1 treatment (Fig. 1D and E). Consistent with
COX-2 protein expression, IL-1β also increased the production of PGE2,
a major antiﬁbrotic product of COX-2 activity. However, the increase
was signiﬁcantly reduced by TGF-β1 treatment and SAHA was also able
to enhance IL-1β-induced PGE2 production in F-NL treated with or
without TGF-β1 (Fig. 1F). The results suggest that SAHA can prevent
TGF-β1-induced downregulation of COX-2 protein expression and re-
duction of COX-2 activity (PGE2 production) during the process of lung
ﬁbroblast activation.
3.2. TGF-β1-induced COX-2 downregulation is not clearly associated with
epigenetic modiﬁcations
Since previous studies have demonstrated association of histone
modiﬁcations (e.g. histone deacetylation and H3K27me3) and DNA
methylation with COX-2 repression in IPF and human gastric carcinoma
[3,5,24], we went on to investigate the potential role of epigenetic
modiﬁcations in TGF-β1-induced COX-2 downregulation in F-NL and
whether these modiﬁcations could be altered by SAHA. Chromatin
Immunoprecipitation (ChIP) analysis was performed using antibodies
recognizing the acetylated form of histone H3 and H3K27me3 and two
sets of primers (set A and B) amplifying the COX-2 promoter regions
highlighted in Fig. 2A. As pilot data showed no eﬀect of IL-1β on the
association of acetylated histone H3 and H3K27me3 with the COX-2
promoter in TGF-β1-stimulated cells (data not shown), we decided to
focus our attention on TGF-β1 and SAHA to assess their eﬀect on his-
tone modiﬁcations without any additional inﬂuence of IL-1β. Com-
parable results were obtained using the two ChIP primer sets
(Fig. 2C–E). As shown in Fig. 2B and C, TGF-β1 stimulation induced a
slight enrichment of acetylated H3 at the two regions of the COX-2
promoter; pre-treatment with SAHA reduced H3 acetylation alone and
prevented TGF-β1-induced increase, but the eﬀect was not statistically
signiﬁcant. TGF-β1 stimulation did not have any eﬀect on H3K27me3
association with the COX-2 promoter, but pre-treatment with SAHA,
either alone or in combination with TGF-β1, reduced H3K27me3 as-
sociation, with signiﬁcant reduction (p < 0.05) observed only with
primer set A in TGF-β1-stimulated cells (Fig. 2D and E).
Bisulﬁte sequencing was then performed to identify the DNA me-
thylation status of the COX-2 promoter region (−692 to +168) in F-NL
Fig. 2. Eﬀect of SAHA on histone modiﬁcations associated
with the COX-2 promoter. A, Schematic representation of
COX-2 promoter region identifying single CpG sites (ver-
tical bar), binding sites for transcription factors NF-κB
(Nuclear factor-κB), C/EBP (CCAAT/enhancer binding
protein) and CRE (cAMP-response element), transcription
start site (+1), translational coding site ATG and regions
ampliﬁed by ChIP primers (ChIP-set A and ChIP-set B). B–E,
F-NL from 3 donors were pre-treated with SAHA (5 μM) for
1 h prior to incubation with TGF-β1 (2 ng/ml) for 72 h.
ChIP assay was performed using antibodies against acety-
lated histone H3 (B, C) and H3K27me3 (D, E) and the as-
sociated COX-2 promoter DNA was detected by real-time
PCR using ChIP-set A (B, D) and ChIP-set B (C, E) primers.
Data are normalized to the input control and reported as
mean ± SEM of three biological replicates. *p < 0.05.
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and to explore whether TGF-β1 could alter the DNA methylation. As
shown in Supplementary Fig. 2, the CpG sites in the region of the COX-2
promoter were mostly unmethylated in F-NL and TGF-β1 treatment did
not markedly alter the methylation status of these CpG sites.
These observations suggest that the epigenetic modiﬁcations, in-
cluding histone deacetylation, H3K27me3 and DNA methylation, are
unlikely involved in the downregulation of COX-2 expression in TGF-
β1-induced ﬁbroblast activation under our experimental conditions and
that the eﬀect of SAHA on preventing COX-2 downregulation is not
mediated by regulating epigenetic modiﬁcations at the COX-2 pro-
moter.
3.3. 3′-UTR-mediated post-transcriptional control is involved in COX-2
regulation by SAHA
COX-2 gene expression analysis highlights a lack of association be-
tween COX-2 mRNA and protein levels, as COX-2 protein expression
was increased by 7.9-fold when SAHA was administered in TGF-β1-
treated F-NL (Fig. 1E), whereas the mRNA levels were comparable
(Fig. 1C). ChIP analysis also suggests a lack of epigenetic modifying
mechanisms in mediating the eﬀect of SAHA on COX-2 expression
(Fig. 2). To evaluate if post-transcriptional mechanisms of gene ex-
pression control that target the COX-2 mRNA 3′-UTR could be re-
sponsible for the apparent discrepancy between COX-2 protein and
mRNA expression by SAHA treatment, the COX-2 mRNA 3′-UTR was
cloned downstream a luciferase gene in the pmirGLO Dual-Luciferase
miRNA Target Expression Vector (Fig. 3A). The vectors, empty or
harbouring the 2.75 Kb COX-2 3′-UTR (Fig. 3B), were then transfected
into F-NL cells treated with SAHA and TGF-β1.
The luciferase activity was therefore regulated post-tran-
scriptionally by the COX-2 3′-UTR. Compared with cells transfected
with empty vector, relative luciferase activity was reduced 2.8-fold in
control cells transfected with the COX-2 3′-UTR with or without IL-1β
(Fig. 3C), suggesting that the COX-2 3′-UTR can post-transcriptionally
downregulate ﬁreﬂy luciferase protein expression (activity) in un-
treated F-NL. TGF-β1 treatment with or without IL-1β stimulation in-
duced a further modest, but insigniﬁcant, reduction of the relative lu-
ciferase activity compared with control cells. In contrast, SAHA
treatment induced a marked increase of relative luciferase activity,
particularly when IL-1β was applied, 3.2-fold and 6.1-fold increases
with respect to control cells (p < 0.05) and TGF-β1-treated cells
(p < 0.001), respectively (Fig. 3C). The luciferase assay data suggest
that COX-2 protein expression is regulated post-transcriptionally and
that SAHA can act on the COX-2 gene post-transcriptional machinery to
increase IL-1β-induced COX-2 protein expression, possibly as a con-
sequence of increased COX-2 translation and/or mRNA stability.
3.4. SAHA stabilizes COX-2 mRNA
To identify if COX-2 mRNA turnover was modiﬁed by SAHA, an
actinomycin D (ActD) chase experiment was performed. F-NL cells were
cultured following the usual schedule of treatment, but 5 μM ActD was
added after 2 h stimulation with IL-1β. Total mRNA was extracted at 0,
4, 8, and 24 h after ActD addition. In control cells, IL-1β-induced COX-2
mRNA was reduced to 59.7%, 46.0% and 49.2% at 2, 8, and 24 h re-
spectively post ActD addition compared with 100% at 0 h post ActD
addition, suggesting a natural degradation of IL-1β-induced COX-2
mRNA in F-NL (Fig. 4). Compared with control cells, treatment with
SAHA alone markedly reduced IL-1β-induced COX-2 mRNA expression
(0 h), and 68.8%, 63.0% and 75.2% COX-2 mRNA was maintained at 2,
8, and 24 h post ActD addition compared with 100% at 0 h (SAHA
alone), suggesting that SAHA may increase the stability of transcribed
COX-2 mRNA (Fig. 4). TGF-β1 treatment also reduced COX-2 mRNA
expression, but did not alter the natural degradation of COX-2mRNA as
70.7%, 54.1%, and 51.6% COX-2 mRNA was maintained at 2, 8, and
24 h post ActD addition compared with 100% at 0 h (TGF-β1 alone),
similar to control cells (Fig. 4). SAHA treatment did not alter TGF-β1-
induced reduction on COX-2 mRNA expression, but increased the sta-
bility of transcribed COX-2 mRNA as 98.1%, 88.5% and 70.4% COX-2
mRNA was maintained at 2, 8, and 24 h respectively post ActD addition
compared with 100% at 0 h (SAHA+TGF-β1), but the eﬀect of SAHA
was not statistically signiﬁcant (Fig. 4). These observations suggest that
SAHA may cause a modest stabilization of COX-2 mRNA, however, this
eﬀect is unlikely to provide a plausible explanation to the dissociation
Fig. 3. Eﬀect of SAHA on COX-2 3′-UTR luciferase activity.
A, Schematic representation of the luciferase vector used to
study the eﬀect of COX-2 3′-UTR on gene expression. COX-2
3′-UTR was cloned downstream the ﬁreﬂy luciferase gene
(Luc2) in the pmirGLO Dual-Luciferase miRNA Target
Expression Vector that harbours also the Renilla luciferase
(hRLuc-neo fusion) as a control reporter to normalize data.
B, Cloned COX-2 3′-UTR (2.75 Kb) with AUUUA sites, tar-
gets of ARE binding proteins. C, F-NL from 3 donors were
pre-treated with SAHA (5 μM) for 1 h prior to incubation
with TGF-β1 (2 ng/ml) for 48 h. The cells were then
transfected with the empty vector or the vector harbouring
COX-2 3′-UTR. SAHA and TGF-β1 treatments were repeated
for additional 48 h, in combination with IL-1β (1 ng/ml) to
induce COX-2 for the last 24 h. Relative luciferase activity
was calculated as the ratio between ﬁreﬂy luciferase ac-
tivity and Renilla luciferase activity. Data are reported as
mean ± SEM of three biological replicates. *p < 0.05;
***p < 0.001.
Fig. 4. Eﬀect of SAHA on COX-2 mRNA stability. F-NL from 3 donors were pre-treated
with SAHA (5 μM) for 1 h prior to incubation with TGF-β1 (2 ng/ml) for 72 h. COX-2
mRNA expression was induced by incubation with IL-1β (1 ng/ml) to induce COX-2
mRNA for 2 h prior the addition of ActinomycinD (ActD, 5 μM) to inhibit mRNA synthesis.
COX-2 mRNA level was evaluated by qRT-PCR using GAPDH as reference gene (2−ΔΔCT
method). Fold changes from control condition at 0 h ActD were calculated and data are
reported as mean ± SEM of three biological replicates.
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between SAHA-induced increase of COX-2 protein expression and un-
changed mRNA expression in TGF-β1-treated F-NL and to the sig-
niﬁcant induction of COX-2 3′-UTR-regulated luciferase activity by
SAHA over TGF-β1-treated F-NL.
3.5. SAHA induces the downregulation of the ARE binding protein TIA-1
COX-2 3′-UTR harbours many AREs, targets of a family of proteins
termed ARE-binding proteins. These proteins play an important role in
the modulation of their target gene expression, by inﬂuencing mRNA
turnover and translation. In order to evaluate the participation of ARE-
binding proteins in COX-2 regulation by SAHA in our cell system, we
studied the eﬀect of TGF-β1, SAHA and DAC on the mRNA expression of
ELAV1 (HuR), TIA-1 and ZEP36 (TTP) in F-NL cells in the presence of IL-
1β. Compared with control cells, IL-1β and TGF-β1 stimulation had no
eﬀect on ELAV1 (HuR) and TIA-1mRNA expression, pre-treatment with
DAC did not alter ELAV1 and TIA-1 mRNA expression in TGF-β1-sti-
mulated cells; however, pre-treatment with SAHA, but not DAC,
markedly reduced TIA-1, but not ELAV1 mRNA expression in TGF-β1-
stimulated cells (Fig. 5A and B). IL-1β alone induced a downregulation
of ZEP36 and further treatment with TGF-β1, SAHA and DAC did not
alter the downregulation (Fig. 5C). Consistent with mRNA expression,
IL-1β and TGF-β1 stimulation had no eﬀect on TIA-1 protein expression
in F-NL, however, treatment with SAHA, either alone or together with
TGF-β1 and IL-1β, signiﬁcantly reduced TIA-1 protein expression in F-
NL (Fig. 5D–E). Since TIA-1 has been reported to inhibit COX-2 trans-
lation [23], its downregulation induced by SAHA is likely to be asso-
ciated with the consistent upregulation of COX-2 protein expression
(Fig. 1) and increased COX-2 3′-UTR reporter activity (Fig. 3).
3.6. TIA-1 repression via siRNA is associated with COX-2 upregulation
In order to explore if TIA-1 could play a role in the regulation of
COX-2 gene expression, a set of four siRNA probes speciﬁc for TIA-1
were transfected in F-NL cells with or without TGF-β1 treatment, the
cells were then treated with IL-1-β to induce COX-2, and the protein
expression of TIA-1 and COX-2 was analyzed by Western blotting. The
constitutive TIA-1 expression was not aﬀected by TGF-β1 treatment,
but was completely abolished by TIA-1 siRNA in both control and TGF-
β1-treated cells (Fig. 6A and B). The knockdown of TIA-1 was accom-
panied by a signiﬁcant upregulation of IL-1β-induced COX-2 protein
expression in control cells and prevented TGF-β1-induced COX-2
downregulation (Fig. 6A and C). The eﬀect of TIA-1 knockdown on
COX-2 was similar to that of SAHA (Fig. 1D and E), suggesting that the
post-transcriptional control induced by SAHA on COX-2 expression is
largely mediated by the downregulation of TIA-1 and subsequent in-
crease of COX-2 mRNA translation.
4. Discussion
Repressed COX-2 expression and deﬁcient PGE2 have been shown to
contribute to the activation of lung ﬁbroblasts and the excessive de-
position of collagen in pulmonary ﬁbrosis. In ﬁbroblasts obtained from
ﬁbrotic lungs, COX-2 repression has been associated with epigenetic
dysregulation characterized by reduced histone acetylation and in-
creased H3K9 and H3K27 methylation at the COX-2 promoter and
epigenetic inhibitors targeting these histone modiﬁcations are able to
restore COX-2 gene expression and PGE2 production [3,5]. COX-2
downregulation and reduced PGE2 production are also associated with
TGF-β1-induced lung ﬁbroblast activation [4]. The main aim of this
study was to investigate whether epigenetic inhibitors, could prevent
Fig. 5. Eﬀect of epigenetic inhibitors on ARE binding protein gene expression. F-NL from 3 donors were pre-treated with SAHA (5 μM) and DAC (1 μM) for 1 h prior to incubation with
TGF-β1 (2 ng/ml) for 96 h before further incubation with IL-1β (1 ng/ml) to induce COX-2 for the last 4 (for mRNA expression) and 24 (for protein expression) h. A–C, mRNA expression
analysis of HuR, TIA-1 and TTP was performed by qRT-PCR using GAPDH as reference gene (2−ΔΔCT method). Fold changes from control condition (CTL) were calculated. D, A
representative Western blotting showing the eﬀect of SAHA on TIA-1 protein expression using α-Tubulin as loading control. E, Optical densitometry analysis of Western blotting bands.
Data were normalized with the loading control α-tubulin. Fold changes from control condition were calculated. Data are reported as mean ± SEM of three biological replicates.
*p < 0.05.
A. Pasini et al. BBA - Gene Regulatory Mechanisms 1861 (2018) 463–472
469
COX-2 downregulation and reduced PGE2 production in TGF-β1-acti-
vated lung ﬁbroblasts. Among the epigenetic inhibitors we tested, the
pan-HDAC inhibitor SAHA was the most eﬀective to prevent COX-2
downregulation induced by TGF-β1 in F-NL. To our surprise, the eﬀect
of SAHA on COX-2 was not mediated by regulating epigenetic mod-
iﬁcations at the COX-2 promoter, instead was mostly mediated by a
novel TGF-β1-independent post-transcriptional mechanism, through
the downregulation of the translational silencer of COX-2 expression
TIA-1.
We conﬁrmed that TGF-β1-activated lung ﬁbroblasts were asso-
ciated with COX-2 downregulation and reduced PGE2 production as
previously reported [4] and demonstrated that SAHA and the DNA
demethylating agent Decitabine were able to increase COX-2 protein
expression in response to IL-1β, but had no eﬀect on the reduced COX-2
mRNA expression. On the other hand, the G9a inhibitor BIX01294 and
the EZH2 inhibitor DZNep had no eﬀect on the expression of both COX-
2 protein and mRNA, despite that global decreases of H3K9me3 and
H3K27me3 were detected in cells treated with BIX01294 and DZNep,
respectively (data not shown), suggesting that G9a and EZH2 are in-
hibited by the drugs, but the inhibition does not inﬂuence COX-2 ex-
pression in TGF-β1-treated F-NL. This is diﬀerent from ﬁbroblasts de-
rived from IPF patients [5] where G9a and EZH2 are the major actors
driving COX-2 silencing. Further experiments focusing on SAHA re-
vealed that SAHA alone had no eﬀect on COX-2 protein expression, but
increased IL-1β-induced COX-2 expression in cells not treated with
TGF-β1, suggesting that SAHA can act on COX-2 expression in-
dependently of TGF-β1. Although the increase of IL-1β-induced COX-2
protein expression by SAHA was not signiﬁcant compared with IL-1β
alone and could be due to the variability among cell lines derived from
diﬀerent donors, there is a possibility that post-transcriptional regula-
tion induced by SAHA (i.e. the downregulation of the COX-2 transla-
tional silencer TIA-1) could lead to enhanced translation of IL-1β-in-
duced COX-2 mRNA. It is also interesting that, although both COX-2
expression and PGE2 production were reduced in TGF-β1-treated cells
compared with control cells, the enhancing eﬀect of SAHA on both,
particularly PGE2 production, was stronger in TGF-β1-treated cells
compared with control cells (Fig. 1F). Since PGE2 production down-
stream of COX-2 (immediate product PGH2) is inﬂuenced by the bal-
ance between the enzyme that promotes its synthesis (prostaglandin E
synthase, PGES), the enzymes that reduce its synthesis by diverting
PGH2 towards the synthesis of other PGs (e.g. synthases for PGI2, PGD2
and thromboxane A2 (TXA2)) and the enzyme that causes its degrada-
tion (15-hydroxyprostaglandin dehydrogenase (15-PGDH)), therefore, a
strong linear correlation does not always exist between the level of
COX-2 expression and the level of PGE2 production. In our current
study, it is possible that SAHA may alter the balance of the enzymes
inﬂuencing PGE2 production downstream of COX-2 and PGE2
degradation in TGF-β1-treated cells much more than control cells to
favour exaggerated PGE2 production, but this needs to be explored by
further studies.
Since COX-2 silencing in F-IPF is critically associated with histone
deacetylation and methylation [3,5], we then investigated whether
changes in H3 acetylation and H3K27me3 state at the COX-2 promoter
contributed to COX-2 downregulation in TGF-β1-activated ﬁbroblasts
and whether the eﬀect of SAHA was mediated by epigenetic regulation.
Surprisingly, TGF-β1 stimulation induced a slight but insigniﬁcant in-
crease of H3 acetylation at the COX-2 promoter, which was slightly
reduced by SAHA treatment, even though global H3 acetylation was
increased (data not shown). The inhibition of histone acetylation at the
COX-2 promoter by SAHA is consistent with a previous study showing
inhibition of histone H3 and H4 acetylation at the osteopontin gene
promoter by another HDAC inhibitor trichostatin A (TSA) [25]. Fur-
thermore, TGF-β1 stimulation did not cause any signiﬁcant change of
H3K27me3; however, the association of H3K27me3 with the COX-2
promoter region covered by primer set-A was signiﬁcantly inhibited by
SAHA. As H3 acetylation and H3K27me3 are associated with gene ex-
pression and repression, respectively, the histone modiﬁcations we
observed were inconsistent with reduced COX-2 mRNA and protein
expression, suggesting a dissociation between repressive histone mod-
iﬁcations and COX-2 downregulation in TGF-β1-activated ﬁbroblasts.
This is further supported by the fact that the G9a and EZH2 inhibitors
had no eﬀect on the COX-2 downregulation, which also suggests that
the eﬀect of SAHA on COX-2 is unlikely mediated by reducing
H3K27me3.
It is interesting that methylation of the CpG sites at the COX-2
promoter was not diﬀerent between TGF-β1-treated and control F-NL
cells. This is consistent with a previous report [26] and suggests that
DNA methylation is also not involved in the COX-2 downregulation in
TGF-β1-activated ﬁbroblasts, despite that it is involved in COX-2 re-
pression in ﬁbrotic lung ﬁbroblasts [5]. However, increased COX-2
protein expression was observed with the demethylating agent DAC in
TGF-β1-activated ﬁbroblasts. Although it is possible that DAC may
upregulate COX-2 expression indirectly by demethylating other hy-
permethylated and downregulated targets, such as the transcriptional
regulator chromosome 8 open reading frame 4 (c8orf4) [26], this is
unlikely in our current study as COX-2 mRNA expression was not en-
hanced by DAC.
This dissociation between COX-2 downregulation and epigenetic
repression in TGF-β1-activated ﬁbroblasts is clearly diﬀerent from the
COX-2 silence in ﬁbrotic lung ﬁbroblasts, which is associated with
histone deacetylation and H3K9 and H3K27 methylation as well as DNA
methylation [3,5]. The diﬀerence may be explained by the length of
TGF-β1 treatment, since TGF-β1 could both stimulate and repress COX-
2 expression depending on how long the treatment is maintained. We
Fig. 6. Eﬀect of TIA-1 knockdown on COX-2 expression. F-
NL from 3 donors were transfected with TIA-1 siRNA or
control siRNA (CTL) and then treated with or without TGF-
β1 (2 ng/ml) for 48 h. The transfection and the treatments
were then repeated for additional 48 h in combination with
IL-1β (1 ng/ml) to induce COX-2 for the last 24 h. A, A re-
presentative Western blotting showing the eﬀect of TIA-1
siRNA on TIA-1 and COX-2 protein expression. B–C, Optical
densitometry analysis of Western blotting bands. Data were
normalized with the loading control α-Tubulin. Fold
changes from control condition treated with control siRNA
were calculated and data are reported as mean ± SEM of
three biological replicates. *p < 0.05; **p < 0.01,
***p < 0.001.
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previously reported that TGF-β1 induced both COX-2 mRNA and pro-
tein expression for up to 24 h in F-NL and an increased association of H3
acetylation with the COX-2 promoter for up to 4 h, similar to the eﬀect
of IL-1β [3]. We showed in this study that TGF-β1 treatment for 72 h
did not induce COX-2 expression in the same cells on its own and sig-
niﬁcantly reduced IL-1β-induced COX-2 expression and that this
downregulation was not clearly associated with epigenetic repression.
These observations suggest a shift from an epigenetically active to
epigenetically neutral state at the COX-2 promoter from 24 h to 72 h of
TGF-β1 treatment in F-NL. It is conceivable that a further shift to an
epigenetically repressive state at the COX-2 gene promoter may occur if
TGF-β1 treatment is prolonged beyond 72 h. It is also possible that TGF-
β1 treatment alone may not be suﬃcient to induce epigenetic silencing
of the COX-2 gene, although it is enough to induce COX-2 down-
regulation and ﬁbroblast activation.
Since COX-2 downregulation is not primarily regulated by chro-
matin-dependent mechanisms in TGF-β1-activated ﬁbroblasts and
SAHA upregulates COX-2 protein expression, but not mRNA expression,
it is possible that the eﬀect of SAHA on COX-2 may be mediated by a
post-transcriptional mechanism. Our data using a COX-2 mRNA 3′-UTR
luciferase reporter assay support this hypothesis, since an increased
relative luciferase activity was detected in SAHA-treated cells, which
indicates increased COX-2 mRNA stabilization and/or translation.
Further studies on COX-2 mRNA stability shows that COX-2 mRNA
decay was slowed down by SAHA compared with TGF-β1-treated cells;
however, the eﬀect was not statistically signiﬁcant. Furthermore, IL-1β-
induced COX-2 mRNA in SAHA-treated cells remained low, similar to
that in cells treated with TGF-β1 alone, and SAHA showed no eﬀect on
the expression of HuR and TTP, ARE binding proteins promoting COX-2
mRNA stabilization [27] and degradation [14], respectively, although
TTP expression was reduced by IL-1β. These observations could not
explain the discrepancy between high level of COX-2 protein and low
level of mRNA, as well as the signiﬁcantly increased COX-2 mRNA 3′-
UTR reporter activity in SAHA-treated TGF-β1-activated ﬁbroblasts and
strongly suggest that mRNA stability is unlikely to contribute to COX-2
upregulation by SAHA and that an increased mRNA translation could
play a more signiﬁcant role. Interestingly, TIA-1, an ARE-binding
translational silencer of COX-2 expression [15,17], was downregulated
at both mRNA and protein levels by SAHA, either alone or with TGF-β1,
and independently of IL-1β stimulation, suggesting that TIA-1 is likely
to play a role in SAHA-mediated COX-2 upregulation. Indeed, TIA-1
depletion via siRNA resulted in a signiﬁcant increase of IL-1β-induced
COX-2 protein expression in both control and TGF-β1-treated F-NL,
which is in line with COX-2 upregulation associated with TIA-1
downregulation induced by SAHA. This ﬁnding is consistent with pre-
vious reports showing increased translation of IL-1β-induced COX-2
mRNA by TIA-1 depletion in human osteoarthritis chondrocytes [28]
and increased COX-2 protein expression, but not COX-2 transcription or
mRNA turnover in TIA-1 null macrophages [15] and ﬁbroblasts [17].
Furthermore, binding of TIA-1 to the proximal region of the 3′-UTR of
COX-2 following IL-1β has also been demonstrated by electrophoretic
mobility shift assay (EMSA) in renal mesangial cells [29] and defective
RNA binding of TIA-1 has been shown to promote COX-2 expression in
colon cancer cells [17]. These observations and our data corroborate
the role of TIA-1 as an inhibitor for COX-2 mRNA translation and
strongly suggest that the eﬀect of SAHA on COX-2 upregulation is lar-
gely mediated through the downregulation of TIA-1 and increased
translation of COX-2 mRNA. Notably, TIA-1 depletion in F-NL also re-
sulted in a signiﬁcant downregulation of the ﬁbrotic markers α-smooth
muscle actin (α-SMA) and collagen 1 (data not shown), suggesting TIA-
1 could be critically involved in the regulation of other antiﬁbrotic and
proﬁbrotic genes and could be a potential target for antiﬁbrotic inter-
vention. This is also consistent with the antiﬁbrotic eﬀect of SAHA [30].
It is possible that the antiﬁbrotic eﬀect of SAHA could be partially
mediated through the downregulation of TIA-1, although how SAHA
regulates the downregulation remains to be explored. It is also possible
that non-coding RNAs, such as microRNAs (miRNAs), may play a role in
mediating the eﬀect of SAHA on COX-2 and TIA-1, since some miRNAs,
such as miRNA-199a, miRNA-145a and miR-26a, have been reported to
target and inhibit speciﬁcally COX-2 [31,32] and HDAC inhibitors, such
as SAHA, can modulate the expression of miRNAs implicated in ﬁbrosis,
such as miR-15a, miR-16 and miR-29b and Let-7b [33–35]. Moreover,
TIA-1 mRNA 3′-UTR has been indicated as a putative target of some of
the previously reported miRNAs involved in ﬁbrosis, such as miR-16,
miR-15, and miR-26b, by the experimentally validated microRNA-
target interactions database (miRTarBase, http://mirtarbase.mbc.nctu.
edu.tw/index.php.). Therefore, TIA-1 downregulation associated with
SAHA treatment could be mediated post-transcriptionally by miRNAs.
It is worth noting that the eﬀect of SAHA on COX-2 upregulation in
lung ﬁbroblasts appears to be independent of the eﬀect of TGF-β1 on
COX-2 downregulation. This is evidenced by the observations that
SAHA upregulated IL-1β-induced COX-2 protein expression and COX-2
mRNA 3′-UTR-controlled reporter gene expression with or without the
presence of TGF-β1 and that SAHA downregulated TIA-1 mRNA and
protein expression, but TGF-β1 had no eﬀect. In addition, we also found
that SAHA did not have any eﬀect on the phosphorylation (activation)
of SMAD2/3 (data not shown), the intracellular proteins that transduce
extracellular signals from TGF-β1. Therefore, the eﬀect of SAHA on
COX-2 in lung ﬁbroblasts appears not mediated by interfering with
TGF-β1 signalling or directly antagonizing the eﬀect TGF-β1 on COX-2
downregulation, although as a net eﬀect SAHA did prevent COX-2
downregulation in TGF-β1-activated ﬁbroblasts. The molecular me-
chanisms underlying the COX-2 downregulation by TGF-β1 are unclear
so far.
In conclusion, our data demonstrate that SAHA can upregulate COX-
2 expression and prevent COX-2 downregulation in TGF-β1-activated
ﬁbroblasts. The eﬀect is TGF-β1-independent and chromatin-in-
dependent and is mostly mediated by a novel post-transcriptional me-
chanism through the downregulation of the translational silencer of
COX-2 expression TIA-1. This novel mechanism may represent a pro-
mising strategy to restore the expression of COX-2 and other antiﬁbrotic
genes in pulmonary ﬁbrosis.
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